<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851083</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-13-0038</org_study_id>
    <secondary_id>R01NS077963</secondary_id>
    <nct_id>NCT01851083</nct_id>
  </id_info>
  <brief_title>Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury</brief_title>
  <official_title>A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric severe traumatic brain injury (TBI) is the leading cause of death and disability in&#xD;
      children ages 1-14 years old. There are no effective therapies to treat secondary brain&#xD;
      injury and the post-injury response of CNS apoptosis and neuroinflammation. This study is a&#xD;
      follow-up trial from a previously performed Phase I trial that demonstrated the safety and&#xD;
      potential CNS structural preservation effect of intravenous autologous bone marrow&#xD;
      mononuclear cells (BMMNC) after severe TBI in children. (Cox, 2011) The study is designed as&#xD;
      a prospective, randomized, placebo controlled, blinded Phase 2 safety/biological activity&#xD;
      study. The investigators hope to determine the effect of intravenous infusion of autologous&#xD;
      BMMNCs on brain structure and neurocognitive/functional outcomes after severe TBI in&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Multicenter, randomized, blinded, placebo controlled, Bayesian adaptive dose&#xD;
      escalation design.&#xD;
&#xD;
      Study Intervention: Single dose administered within 48 hours from time of injury. Controls&#xD;
      will undergo a sham harvest and receive similarly labeled/external appearance and volume of&#xD;
      0.9% NaCl. BMMNC's will be harvested and undergo processing under cGMP conditions to obtain&#xD;
      6x10^6 cells/kg or 10x10^6 cells/kg weight. The cellular product/placebo will be infused&#xD;
      within 48 hours of injury.&#xD;
&#xD;
      Safety Monitoring &amp; Follow-Up: Subjects will be monitored for infusion related toxicity&#xD;
      post-infusion through hospital discharge and follow-up return study visits. Laboratory and&#xD;
      imaging studies will be repeated at the 1, 6, and 12-month follow-up visits. A medical safety&#xD;
      monitor (MSM) will review blinded SAE reports following post-infusion Day 14 for each subject&#xD;
      in real time to ensure good clinical practice and to quickly identify safety concerns. The&#xD;
      MSM will remain blinded to the treatment assignment, unless the NINDS appointed DSMB approves&#xD;
      unblinding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 12, 2020</completion_date>
  <primary_completion_date type="Actual">September 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brain white matter and gray matter structural preservation on diffusion tensor magnetic resonance imaging (DTMRI)</measure>
    <time_frame>one year post infusion</time_frame>
    <description>DTMRI quantitative indices of both macro and microscopic integrity will be evaluated and compared to DTMRI of immediate post-injury treated and non-treated controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNS white matter and gray matter preservation in regions of interest and improves functional and neurocognitive deficits in children after TBI</measure>
    <time_frame>one year post infusion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Infusional toxicity safety evaluations</measure>
    <time_frame>7 days post-infusion</time_frame>
    <description>Murray Score and liver function tests</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>autologous bone marrow mononuclear cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow mononuclear cells</intervention_name>
    <description>BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.</description>
    <arm_group_label>autologous bone marrow mononuclear cells</arm_group_label>
    <other_name>BMMNCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Infusion</intervention_name>
    <description>Placebo infusion of 0.9% Sodium Chloride</description>
    <arm_group_label>placebo infusion</arm_group_label>
    <other_name>Saline Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 5 and 17 years of age on the day of injury,&#xD;
&#xD;
          2. Glasgow Coma Score (GCS) between 3 and 8, (best un-medicated post-resuscitation score&#xD;
             during screening),&#xD;
&#xD;
          3. Ability to obtain legally authorized representative (LAR) consent, and complete the&#xD;
             BMMNC/Sham harvest and cell/placebo infusion within 48 hours of the initial injury,&#xD;
&#xD;
          4. Ability to speak English or Spanish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of: a. previous brain injury, b. intellectual deficiency or psychiatric&#xD;
             condition, defined as inability to independently function in a regular classroom that&#xD;
             may invalidate our ability to assess post-injury changes in cognition or behavior&#xD;
             (ADHD and/or other learning disabilities are NOT an exclusion), c. neurologic&#xD;
             impairment and/or deficit, d. seizure disorder requiring anti-convulsant therapy, e.&#xD;
             recently treated infection, f. renal disease or altered renal function&#xD;
             (post-resuscitation serum creatinine &gt; 1.5 mg/dL), g. hepatic disease or altered liver&#xD;
             function (post-resuscitation, non-contusion related SGPT &gt; 150 Î¼/L and/or T. Bilirubin&#xD;
             &gt;1.3 mg/dL), h. cancer, i. immunosuppression as defined by WBC &lt; 3, 000 cells/ml at&#xD;
             admission, j. HIV+, k. chemical or ETOH dependency, l. history of child abuse, m.&#xD;
             premature birth (&lt;37 weeks GA/2500 grams) resulting in cognitive/physical disabilities&#xD;
             and/or developmental delay.&#xD;
&#xD;
          2. Obliteration of perimesencephalic cistern on initial head CT/MRI suggesting prolonged&#xD;
             hypoxic ischemic insult/herniation syndrome.&#xD;
&#xD;
          3. Initial hospital ICP &gt; 40 mm Hg.&#xD;
&#xD;
          4. Hemodynamic instability at the time of screening defined as SBP &lt;90 mmHg, ongoing&#xD;
             fluid resuscitation and/or requirement for inotropic support to maintain MAP at or&#xD;
             above normal for age - does not include CPP based inotropic support. IVF alone does&#xD;
             not exclude from enrollment.&#xD;
&#xD;
          5. Uncorrected coagulopathy at the time of bone marrow harvest defined as INR &gt; 1.6, PTT&#xD;
             &gt; 38 sec; PLT&lt; 100,000; Fibrinogen &lt; 100 g/dL.&#xD;
&#xD;
          6. Unstable pelvic fractures defined as requiring early operative fixation.&#xD;
&#xD;
          7. Pulmonary contusions defined as a chest x-ray with non-anatomic opacification and/or&#xD;
             PaO2:FiO2 ratio &lt; 250 associated with the mechanism of injury.&#xD;
&#xD;
          8. Greater than AAST Grade 3 solid or hollow visceral injury of the abdomen and/or pelvis&#xD;
             as diagnosed by CT or other imaging.&#xD;
&#xD;
          9. Spinal cord injury diagnosed by CT/MR imaging or clinical findings.&#xD;
&#xD;
         10. Persistent hypoxia defined as SaO2 &lt; 94% for &gt; 30 minutes occurring at any time from&#xD;
             hospital admission to time of consent.&#xD;
&#xD;
         11. Positive pregnancy test, if applicable.&#xD;
&#xD;
         12. Concurrent participation in an interventional drug/device research study.&#xD;
&#xD;
         13. Unwillingness to return for follow-up visits.&#xD;
&#xD;
         14. Contraindications to MRI.&#xD;
&#xD;
         15. Penetrating brain injury.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles S Cox, Jr., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital I University of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 5, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <disposition_first_submitted>November 16, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 20, 2020</disposition_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Charles Cox</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>TBI</keyword>
  <keyword>pediatric</keyword>
  <keyword>acute</keyword>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

